Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company that discovers and develops targeted therapies for patients with cancers defined by specific biological markers. The company focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Aprea Therapeutics develops small molecule inhibitors designed to exploit genetic mutations in cancer, aiming to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company was originally incorporated as Aprea Therapeutics AB in 2002 and began principal operations in 2006. On September 20, 2019, Aprea Therapeutics AB became a wholly-owned subsidiary of Aprea Therapeutics, Inc. Following its acquisition of Atrin Pharmaceuticals Inc. ("Atrin") in May 2022, Aprea Therapeutics shifted its focus to assets acquired from Atrin and those developed internally. The company's approach, known as synthetic lethality, involves inhibiting "make up" genes that compensate for damaged gene pathways in cancer cells, thereby selectively killing cancer cells with defined mutations while minimizing effects on normal cells.